Mike Youle

Summary

Affiliation: Royal Free Hospital
Country: UK

Publications

  1. ncbi A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection
    M Youle
    Royal Free Centre for HIV Medicine, Royal Free Hospital, London, UK
    HIV Med 8:241-50. 2007
  2. ncbi HIV-associated antiretroviral toxic neuropathy (ATN): a review of recent advances in pathophysiology and treatment
    Mike Youle
    Royal Free Centre for HIV Medicine, Royal Free Hospital, London
    Antivir Ther 10:M125-9. 2005
  3. ncbi Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients
    Mike Youle
    Royal Free Centre for HIV Medicine, Royal Free Hospital, London NW3 2QG, UK
    J Antimicrob Chemother 60:1195-205. 2007
  4. ncbi Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy
    Mike Youle
    Royal Free Centre for HIV Medicine, Royal Free Hospital, London, UK
    CNS Drugs 21:25-30; discussion 45-6. 2007
  5. ncbi Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations
    Mike Youle
    Royal Free Hospital Centre for HIV Medicine, Royal Free Hospital, London, UK
    HIV Clin Trials 7:86-96. 2006
  6. ncbi Stability of antiretroviral regimens in patients with viral suppression
    Rebecca K Lodwick
    Research Department of Infection and Population Health, Division of Population Health, Royal Free and University College Medical School, London, UK
    AIDS 22:1039-46. 2008
  7. ncbi Data linkage reduces loss to follow-up in an observational HIV cohort study
    Teresa Hill
    Research Department of Infection and Population Health, UCL Medical School, London, UK
    J Clin Epidemiol 63:1101-9. 2010
  8. ncbi Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study
    Tristan J Barber
    St Stephen s AIDS Trust Clinical Trials Unit, Chelsea and Westminster NHS Foundation Trust, London, UK
    Antivir Ther 16:805-14. 2011
  9. ncbi Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy
    Caroline A Sabin
    Royal Free and University College Medical School, Royal Free NHS Trust, London, UK
    AIDS 18:2145-51. 2004
  10. ncbi Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study
    R J C Gilson
    Centre for Sexual Health and HIV Research, Research Department of Infection and Population Health, University College London, The Mortimer Market Centre, Camden Primary Care Trust, London, UK
    HIV Med 11:152-60. 2010

Detail Information

Publications43

  1. ncbi A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection
    M Youle
    Royal Free Centre for HIV Medicine, Royal Free Hospital, London, UK
    HIV Med 8:241-50. 2007
    ..Acetyl-L-carnitine (ALCAR) enhances neurotrophic support of sensory neurones, potentially providing symptom relief and nerve regeneration...
  2. ncbi HIV-associated antiretroviral toxic neuropathy (ATN): a review of recent advances in pathophysiology and treatment
    Mike Youle
    Royal Free Centre for HIV Medicine, Royal Free Hospital, London
    Antivir Ther 10:M125-9. 2005
  3. ncbi Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients
    Mike Youle
    Royal Free Centre for HIV Medicine, Royal Free Hospital, London NW3 2QG, UK
    J Antimicrob Chemother 60:1195-205. 2007
    ..This review discusses the relative strengths and weaknesses of boosted PIs in current practice...
  4. ncbi Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy
    Mike Youle
    Royal Free Centre for HIV Medicine, Royal Free Hospital, London, UK
    CNS Drugs 21:25-30; discussion 45-6. 2007
    ..Further placebo-controlled studies of both treatment and prophylaxis have been completed and are under analysis to characterise further the usefulness of this pathogenesis-based therapy for ATN...
  5. ncbi Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations
    Mike Youle
    Royal Free Hospital Centre for HIV Medicine, Royal Free Hospital, London, UK
    HIV Clin Trials 7:86-96. 2006
    ..g., ENF) for triple-class-experienced patients...
  6. ncbi Stability of antiretroviral regimens in patients with viral suppression
    Rebecca K Lodwick
    Research Department of Infection and Population Health, Division of Population Health, Royal Free and University College Medical School, London, UK
    AIDS 22:1039-46. 2008
    ..To study the rate of treatment change due to toxicities in patients who achieved viral suppression within 6 months of starting antiretroviral therapy and who have never experienced virological failure...
  7. ncbi Data linkage reduces loss to follow-up in an observational HIV cohort study
    Teresa Hill
    Research Department of Infection and Population Health, UCL Medical School, London, UK
    J Clin Epidemiol 63:1101-9. 2010
    ..To ascertain the degree of loss to follow-up in a cohort and to identify its predictors...
  8. ncbi Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study
    Tristan J Barber
    St Stephen s AIDS Trust Clinical Trials Unit, Chelsea and Westminster NHS Foundation Trust, London, UK
    Antivir Ther 16:805-14. 2011
    ..We analysed the influence of gender on use and outcomes of first-line HAART in a UK cohort...
  9. ncbi Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy
    Caroline A Sabin
    Royal Free and University College Medical School, Royal Free NHS Trust, London, UK
    AIDS 18:2145-51. 2004
    ..To investigate the characteristics and clinical, immunological and virological outcomes for individuals presenting for care with low CD4 cell counts...
  10. ncbi Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study
    R J C Gilson
    Centre for Sexual Health and HIV Research, Research Department of Infection and Population Health, University College London, The Mortimer Market Centre, Camden Primary Care Trust, London, UK
    HIV Med 11:152-60. 2010
    ..This study was designed to determine the incidence of a discordant response at two time-points, soon after 6 months and at 12 months, and to determine the relationship with clinical outcomes...
  11. ncbi Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers
    Caroline A Sabin
    Department of Primary Care and Population Sciences, Royal Free and UC Medical School, Pond St, London, UK
    AIDS 20:67-71. 2006
    ..To describe the characteristics of deaths that occur among HIV-positive individuals in the HAART era...
  12. ncbi Long-term effect of acetyl-L-carnitine for antiretroviral toxic neuropathy
    Christian Herzmann
    Royal Free Centre for HIV Medicine, Royal Free Hospital, London, United Kingdom
    HIV Clin Trials 6:344-50. 2005
    ..Treatment with acetyl-L-carnitine (ALCAR) has shown short-term symptomatic and histological improvement. Long-term effects have not been investigated...
  13. ncbi The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy
    Colette J Smith
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, UK
    AIDS 17:963-9. 2003
    ..To study the long-term CD4 cell responses to highly active antiretroviral therapy (HAART) in treatment-naive patients whose viral loads remained below 500 copies/ml for prolonged periods...
  14. ncbi Viral breakthrough after suppression with highly active antiretroviral therapy: experience from 233 individuals with viral loads of less than 50 copies/ml followed for up to 4 years
    Fiona C Lampe
    Royal Free Centre for HIV Medicine, London, UK
    AIDS 17:768-70. 2003
  15. ncbi Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004
    Fiona C Lampe
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Hospital, Rowland Hill Street, London, England
    Arch Intern Med 167:692-700. 2007
    ..The success of clinical care for human immunodeficiency virus infection may vary across demographic groups, because of patient- and health care-related factors...
  16. ncbi Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy
    Andrew M Hart
    Blond McIndoe Centre, Royal Free and University College Medical School, London, UK
    AIDS 18:1549-60. 2004
    ..HIV RNA load, CD4 and CD8 cell counts did not alter significantly throughout the study. CONCLUSIONS: ALCAR treatment improves symptoms, causes peripheral nerve regeneration and is proposed as a pathogenesis-based treatment for DSP...
  17. ncbi Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen
    Mike Youle
    Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
    J Acquir Immune Defic Syndr 29:58-61. 2002
    ..Thus, a substantial proportion of patients who had failed to respond virologically to PI-containing regimens can achieve profound and sustained virologic suppression with a multidrug regimen...
  18. ncbi The effect of transmitted HIV-1 drug resistance on pre-therapy viral load
    Linda Harrison
    HIV and Infections Group, MRC Clinical Trials Unit, London, UK
    AIDS 24:1917-22. 2010
    ..Reduced replication capacity of viruses expressing drug resistant mutations implies that patients with transmitted drug resistance (TDR) could have lower HIV RNA viral load than those infected with wild-type virus...
  19. ncbi Late diagnosis in the HAART era: proposed common definitions and associations with mortality
    Caroline A Sabin
    Research Department of Infection and Population Health, UCL Medical School, London, UK
    AIDS 24:723-7. 2010
    ....
  20. ncbi Factors influencing lopinavir and atazanavir plasma concentration
    Wolfgang Stöhr
    MRC Clinical Trials Unit, London, UK
    J Antimicrob Chemother 65:129-37. 2010
    ..The aim of this study was to evaluate which demographic factors and concomitant drugs are associated with lopinavir and atazanavir plasma concentration...
  21. ncbi The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy
    C A Sabin
    Department of Primary Care and Population Science, Royal Free and UC Medical School, London, UK
    HIV Med 10:35-43. 2009
    ....
  22. ncbi Strategies of HIV management--when to switch
    Mike Youle
    Royal Free Centre for HIV Medicine, Royal Free Hospital, London, UK
    AIDS 16:S151-5. 2002
  23. ncbi Strategies of HIV management--when to start
    Mike Youle
    Royal Free Centre for HIV Medicine, Royal Free Hospital, London, UK
    AIDS 16:S145-9. 2002
  24. ncbi Clinical epidemiology of HIV-associated end-stage renal failure in the UK
    Loveleen Bansi
    University College London Medical School, London, UK
    AIDS 23:2517-21. 2009
    ..To describe the clinical epidemiology of HIV-associated end-stage renal failure (HIV/ESRF) from 1998 to 2007 in the United Kingdom...
  25. ncbi Systemic acetyl-L-carnitine eliminates sensory neuronal loss after peripheral axotomy: a new clinical approach in the management of peripheral nerve trauma
    Andrew McKay Hart
    University Department of Surgery, Blond-McIndoe Centre, Royal Free and University College Medical School, London, UK
    Exp Brain Res 145:182-9. 2002
    ....
  26. ncbi Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy
    Mike Youle
    Royal Free Centre for HIV Medicine, Royal Free Hospital, Pond Street, London NW3 2QG
    J Int Assoc Physicians AIDS Care (Chic) 2:102-5. 2003
    ..Analogous to post-exposure prophylaxis, HIV prevention may be achieved by pre-exposure prophylaxis in some settings. Research in this potential strategy may be rewarding...
  27. ncbi TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals
    Brian Angus
    Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK
    AIDS 22:737-40. 2008
    ..We aimed to see if structured treatment interruption (STI) could be supported safely with the use of two cycles of IL-2 (4.5 MIU q12h subcutaneously 5 days) before STI to prolong the time before therapy restarted...
  28. ncbi A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial
    Ulrik B Dragsted
    Hvidovre University Hospital, Copenhagen, Denmark
    Antivir Ther 10:735-43. 2005
    ..To assess the rate of protocol-defined treatment failure and safety of lopinavir/ritonavir (LPV/r) and saquinavir/ritonavir (SAQ/r)...
  29. ncbi Transient increase in plasma HIV-1 viral load and associated weight gain after thalidomide dosing
    Steve Teo
    AIDS 16:2355-6. 2002
  30. ncbi How to treat without the need to deliver continuous HIV suppression? 9th Conference on Retroviruses and Opportunistic Infections. February 24-28, 2002 - Seattle
    Mike Youle
    IAPAC Mon 8:114-8. 2002
  31. ncbi Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?
    Antonia L Moore
    Department of Primary Care and Population Sciences and Centre for HIV Medicine, Royal Free and University College School of Medicine, Hampstead, London NW3 2PF, UK
    AIDS 16:615-8. 2002
    ....
  32. ncbi European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults
    N Clumeck
    Saint Pierre University Hospital, Department of Infectious Diseases, Brussels, Belgium
    HIV Med 9:65-71. 2008
    ....
  33. ncbi Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002
    Fiona C Lampe
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, England
    Arch Intern Med 166:521-8. 2006
    ..We examined risk of initial virological failure of CART according to the year of starting therapy...
  34. ncbi Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
    Gerd Fatkenheuer
    Department of Internal Medicine, Division of Infectious Diseases, Haus 11, University of Cologne, Joseph Stelzmann Strasse 9, D 50924 Cologne, Germany
    Nat Med 11:1170-2. 2005
    ..6 log(10) copies/ml at all twice daily doses >or=100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach...
  35. ncbi Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial
    Ulrik Bak Dragsted
    Hvidovre University Hospital, Hvidovre, Denmark
    J Infect Dis 188:635-42. 2003
    ..A greater number of treatment-limiting adverse events were observed in the Idv/Rtv arm, relative to the Sqv/Rtv arm. In conclusion, Rtv-boosed Sqv and Idv were found to have comparable antiretroviral effects in the doses studied...
  36. ncbi Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies
    Bonaventura Clotet
    , and HIV Unit Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain
    J Acquir Immune Defic Syndr 45:479-81. 2007
  37. ncbi Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir
    Mike Westby
    Pfizer Global Research and Development, Sandwich, United Kingdom
    J Virol 80:4909-20. 2006
    ..Importantly, in all three patients, circulating virus reverted to predominantly CCR5 tropic following cessation of maraviroc...
  38. ncbi Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals
    Mike Youle
    Lancet 364:1036-7. 2004
  39. ncbi A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial
    Zoe Fox
    Copenhagen HIV Programme (CHIP, Hvidovre University Hospital, Copenhagen, Denmark
    Antivir Ther 11:761-70. 2006
    ..Evolutionary distances from baseline were larger in viruses that did not contain M1841/V. More discernable benefits may be seen in patients with fewer drug options as potent cART may eclipse a benefit of M1841/V in COLATE...
  40. ncbi An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial
    Tassos C Kyriakides
    VA Cooperative Studies Program Coordinating Center, West Haven, Connecticut 06516, USA
    Control Clin Trials 24:481-500. 2003
    ..We discuss the rationale behind the OPTIMA Trial design as well as the issues arising from the conduct of a trial that involves three national clinical trial agencies...
  41. ncbi Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine?
    Mike Youle
    AIDS 17:937-8. 2003
  42. ncbi The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells
    Thomas Sternfeld
    Department of Infectious Diseases, Medizinische Poliklinik, University of Munich, Germany
    Antivir Ther 12:769-78. 2007
    ..The influence of ART was analysed in six patients who started their first regimen...
  43. ncbi Kaposi's sarcoma-associated herpesvirus cytotoxic T lymphocytes recognize and target Darwinian positively selected autologous K1 epitopes
    Justin Stebbing
    Cancer Research U.K. Viral Oncology Group, The Wolfson Institute for Biomedical Research, University College London, United Kingdom
    J Virol 77:4306-14. 2003
    ..Furthermore, these epitopes are highly conserved sequences within KSHV isolates from a specific strain but are not conserved between different strains. We conclude that CTL recognition contributes to K1, and therefore to KSHV, evolution...